GALLO, Ciro
 Distribuzione geografica
Continente #
EU - Europa 12.348
NA - Nord America 6.577
AS - Asia 4.950
SA - Sud America 821
Continente sconosciuto - Info sul continente non disponibili 228
AF - Africa 73
OC - Oceania 7
Totale 25.004
Nazione #
RU - Federazione Russa 7.490
US - Stati Uniti d'America 6.494
SG - Singapore 1.786
IE - Irlanda 1.452
CN - Cina 1.162
UA - Ucraina 874
HK - Hong Kong 844
BR - Brasile 701
GB - Regno Unito 642
DE - Germania 601
IT - Italia 470
VN - Vietnam 386
SE - Svezia 245
FI - Finlandia 236
IN - India 176
TR - Turchia 157
GR - Grecia 141
BD - Bangladesh 115
KR - Corea 99
JP - Giappone 78
FR - Francia 59
AR - Argentina 52
CA - Canada 34
AT - Austria 29
EC - Ecuador 26
BE - Belgio 22
IQ - Iraq 21
ID - Indonesia 20
MX - Messico 19
ZA - Sudafrica 17
IR - Iran 16
ES - Italia 14
MA - Marocco 14
EG - Egitto 13
CH - Svizzera 11
CO - Colombia 11
NL - Olanda 10
TW - Taiwan 10
PK - Pakistan 9
PL - Polonia 9
SA - Arabia Saudita 9
VE - Venezuela 9
CL - Cile 8
CZ - Repubblica Ceca 8
TH - Thailandia 8
TN - Tunisia 8
UZ - Uzbekistan 8
BG - Bulgaria 7
DZ - Algeria 7
PH - Filippine 7
JM - Giamaica 6
NP - Nepal 6
AE - Emirati Arabi Uniti 5
EU - Europa 5
PE - Perù 5
PY - Paraguay 5
RO - Romania 5
TT - Trinidad e Tobago 5
AU - Australia 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
GH - Ghana 4
HU - Ungheria 4
JO - Giordania 4
PT - Portogallo 4
CR - Costa Rica 3
KE - Kenya 3
KH - Cambogia 3
NZ - Nuova Zelanda 3
RS - Serbia 3
UY - Uruguay 3
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
BF - Burkina Faso 2
CW - ???statistics.table.value.countryCode.CW??? 2
ET - Etiopia 2
GE - Georgia 2
KG - Kirghizistan 2
MY - Malesia 2
NO - Norvegia 2
OM - Oman 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SV - El Salvador 2
AM - Armenia 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CY - Cipro 1
GP - Guadalupe 1
GT - Guatemala 1
HN - Honduras 1
HT - Haiti 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
Totale 24.775
Città #
Moscow 2.699
Dublin 1.452
Jacksonville 1.280
Chandler 853
Hong Kong 839
Singapore 673
Santa Clara 572
San Jose 469
Ashburn 331
Princeton 234
Bremen 220
Medford 207
Beijing 157
Boardman 154
Bengaluru 142
San Mateo 135
Ho Chi Minh City 130
Ann Arbor 125
Wilmington 120
Roxbury 116
Hefei 111
Seoul 96
Hanoi 88
Woodbridge 86
The Dalles 76
Dallas 65
New York 56
São Paulo 56
Caserta 53
Los Angeles 50
Jinan 49
Des Moines 47
Mountain View 41
Cambridge 39
Munich 39
Nanjing 36
Council Bluffs 29
Houston 28
Rio de Janeiro 28
Naples 24
Milan 23
Zhengzhou 23
Da Nang 22
Vienna 22
Haiphong 20
Orem 20
Rome 20
Brussels 19
Norwalk 19
Belo Horizonte 18
Düsseldorf 17
Guangzhou 16
Hangzhou 16
Nanchang 16
Napoli 16
Turku 15
Helsinki 14
Ningbo 14
Nuremberg 14
Atlanta 13
Changsha 13
Curitiba 12
Seattle 12
Brasília 11
Campodarsego 11
Memphis 11
Ninh Bình 11
Scottsdale 11
Shenyang 11
Tianjin 11
Buffalo 10
Dearborn 10
Haikou 10
Kunming 10
Tokyo 10
Bari 9
Chicago 9
Guarulhos 9
Guayaquil 9
Hải Dương 9
Juiz de Fora 9
Padova 9
Quito 9
Salvador 9
Venice 9
Bắc Ninh 8
Campinas 8
Frankfurt am Main 8
Philadelphia 8
Redwood City 8
Boston 7
Chennai 7
Dhaka 7
Istanbul 7
Johannesburg 7
Manchester 7
Porto Alegre 7
San Francisco 7
Shanghai 7
Stockholm 7
Totale 12.726
Nome #
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients 347
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 310
Association between thraetened pre-term labour and periodontal disease: does a relationship exist? A matched case-control study 203
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial 198
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data 194
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials 194
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial 187
Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections 170
Antiproteinuric Response to Dual Blockade of RAS in Primary Glomerulonephritis: Meta-Analysis and Meta-Regression 165
Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies 164
Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials 157
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study 154
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 149
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study 149
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC 148
A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial 147
Epidemiological study on behavioural and emotional problems in developmental age: prevalence in a sample of Italian children, based on parent and teacher reports. 145
A multivariate strategy for the statistical treatment of chemico-clinical data and the construction of reference regions 145
A phase 2, open label, multicenter, single arm study of tocilizumab on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia (TOCIVID-19 trial): Statistical analysis plan 145
A prognostic index for patients within the intermediate stage of hepatocellular carcinoma 142
Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer 138
Epidemiology of chronic kidney disease in Italy: the CARHES study 138
Atti del Convegno della Società Italiana di Statistica Medica ed Epidemiologia Clinica 138
CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study) 137
Chronic active hepatitis in Italy: a multicentric study on clinical and laboratory data of 1151 cases. A report from the study group for CAH of the Italiana Association for the Study of the Liver 136
Management of hypertension in chronic kidney disease: the Italian multicenter study. 135
Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial 134
Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. 134
High cardiovascular risk in patients with Type 2 diabetic nephropathy: the predictive role of albuminuria and glomerular filtration rate. The NID-2 Prospective Cohort Study. 134
Clinical and histological aspects of chronic HCV infection and cirrhosis 133
Adjuvant chemoendocrine therapy for early breast cancer: is it worthwhile? 133
Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study 131
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group 131
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study 131
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial 131
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study 130
A predictive index of axillary nodal involvement in operable breast cancer 130
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme) 129
Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy 127
[Early assessment of mobility and posture as prognosis indicators] 127
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials 127
First-Line Erlotinib Followed by Second-Line Cisplatin- Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial 126
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer 126
Fattori di rischio per l'infezione tifoidea nell'area geografica del golfo di Napoli 125
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. 125
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. 124
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials 124
Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial 123
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study 123
Activity and toxicity of gemcitabine and gemcitabine plus vinorelbine in advanced non-small-cell lung cancer elderly patients. Phase II data from the MILES (Multicenter Italian Lung cancer in the Elderly Study) randomized trial 123
Prognosis of CKD Patients Receiving Outpatient Nephrology Care in Italy 123
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. 122
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 122
Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma. A Cancer of the Liver Italian Program (CLIP 08)retrospective case-control study 121
Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP) 121
Prognostic significance of circulating immune complexes in a long-term follow-up of breast cancer patients 121
Time spent for activation of non-profit studies in oncology in Italy 121
Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab 121
Prevalence of varicose veins in an Italian elderly population 118
Application of a statistical approach to determining reference intervals in clinical chemistry 118
LETTERS TO THE EDITOR: RISK OF WARFARIN DURING PREGNANCY WITH MECHANICAL VALVE PROSTHESES 118
Morbidity patterns in aged population in southern Italy. A survey sampling 117
Health effects associated with the disposal of solid waste in landfills and incinerators in populations living in surrounding areas: a systematic review 117
Management of hypertension in chronic kidney disease: the italian multicentric study 116
Risk of warfarin during pregnancy with mechanical valve prostheses 116
Efficacia e sicurezza della combinazione colistina-rifampicina in confronto con la colistina in monoterapia nelle infezioni gravi da Acinetobacter baumannii MDR: risultati preliminari 116
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial 115
Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial 115
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 115
Is human hepatocellular carcinoma a hormone-responsive tumor? 115
Differenti modalità di classificazione e significato prognostico delle aritmie ventricolari dopo infarto acuto del miocardio 114
Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey 114
Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer 113
Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non-Small-Cell Lung Cancer 112
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer 112
Consumi, abitudine e atteggiamentei verso alcool, tabacco e caffé. Indagine campionaria in una USL napoletana 112
c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary limphnode metastases 112
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 112
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system 112
Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. Results of a multicentre phase II study 111
Informed versus randomised consent to clinical trials 111
Comparison of predictive accuracy of four prognostic models fr non-metastatic renal cell carcinoma after nephrectomy. A multicentre European study 111
Dental occlusion and body posture in growing subjects. A population-based study in 12-year- old Italian adolescents 110
Piccole storie di malati 110
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials 110
Phase I study of carboplatin, cisplatin and cyclophosphamide without and with lenogastrim for the treatment of ovarian cancer 109
Il rischio di complicanze nel paziente operato: problemi metodologici 109
The role of surgery in transmitting "post-transfusion" hepatitis 109
Comparaison de la précision predictive de quatre modèles pronostiques dans le cancer du rein localisé 109
Prospective Validation of the CLIP Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators 109
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. 108
Immunosuppressive therapy of HBsAg-positive chronic active hepatitis in childhood: a multicentric restrospective study on 139 patients 107
Tamoxifen in the treatmnent of hepatocellular carcinoma: 5 years results of the CLIP-1 multicentre randomised controlled trial 107
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 107
BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. 107
The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care 107
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study 106
Prospective validation of the International Warfarin Pharmacogenetics Consortium algorithm in high-risk elderly people (VIALE study) 106
Statistical design in phase II clinical trials and its application in breast cancer 105
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. 105
Totale 13.170
Categoria #
all - tutte 89.944
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.944


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.166 0 4 3 21 480 5 24 38 46 65 101 379
2022/20233.029 261 53 31 295 432 264 4 177 1.380 17 49 66
2023/20241.039 104 38 101 101 384 30 18 14 3 20 63 163
2024/20252.787 12 28 32 55 408 240 434 274 441 460 211 192
2025/202612.013 383 507 611 635 974 6.995 548 266 451 256 224 163
2026/2027255 112 143 0 0 0 0 0 0 0 0 0 0
Totale 25.004